Abstract 614P
Background
Programmed Death Ligand-1 (PD-L1) is expressed in most type of cancer cells, including osteosarcoma. However, the role of PD-L1 expression in prognosis of osteosarcoma patients remains unclear. Thus, this study aims to investigate the association between PD-L1 expression and prognosis of Osteosarcoma patients.
Methods
Data was gathered from PubMed, PMC, and ScienceDirect databases on September 08, 2022, using keywords associated with PD-L1, Osteosarcoma in relation to the prognosis, which is measured by overall survival (OS), progression free survival (PFS), and event free survival (EFS). Publications included are associated with Osteosarcoma patients that are limited to English manuscripts within the last 10 years. Review articles, publications without full paper, and case report studies are excluded. The quality of each included study was assessed using the Newcastle Ottawa Scale (NOS), JBI Critical Appraisal for Quasi Experimental Studies, and Grading of recommendations, assessment, development, and evaluations (GRADE).
Results
A total of 7 studies consisting of 289 Osteosarcoma patients were included. All 6 studies have good quality based on NOS and one study categorized as include based on JBI. All 7 studies showed that high expression of PD-L1 correlates with poor prognosis of Osteosarcoma patients. Pooled analysis showed that high PD-L1 expression correlates with inferior OS (HR=2.03; 95%CI, 1.12-3.69; p=0.02) and PFS (HR= 1.18; 95%CI, 1.06-1.31; p=0.003). However, no significant association between PD-L1 expression and EFS (HR=1.05; 95%CI, 0.40-2.75; p=0.92). Based on GRADE, the result of this study is moderate in quality, as there is no inconsistency in results and publication biases are minimal.
Conclusions
Current studies demonstrated that high PD-L1 expression is associated with inferior OS and PFS, but not EFS in osteosarcoma patients, which warrants further prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract